Clinical Trials Browser

tozuleristide × Clear all

NCT05316688 2026-02-25

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Phase 1/2 Terminated

8 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

NCT04743310 2025-06-13

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System

Phase 2 Completed

50 enrolled

CNS

Astrocytoma, Brain Neoplasms, Craniopharyngioma, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Germ Cell and Embryonal, Neuroma, Acoustic, Pinealoma, Spinal Cord Neoplasms, Central Nervous System Neoplasms

NCT03579602 2024-06-27

Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery

Phase 2/3 Completed

118 enrolled 21 charts

CNS

Brain Neoplasms, Central Nervous System Neoplasms

NCT02462629 2023-02-21

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Phase 1 Completed

29 enrolled

CNS

Brain Neoplasms, Central Nervous System Neoplasms

NCT02496065 2017-07-13

Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

Phase 1 Completed

30 enrolled

Breast

Breast Neoplasms

NCT02464332 2016-05-26

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Phase 1 Withdrawn

Sarcoma

NCT02234297 2016-04-06

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery

Phase 1 Completed

17 enrolled

CNS

Glioma

NCT02097875 2015-04-21

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Phase 1 Completed

21 enrolled

Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms